We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

If you are unable to listen to this audio, please update your browser or click here to download the file [7.3MB].

Similar to the influenza virus, HIV mutates constantly. But while developing fresh vaccines every year can target influenza, HIV is much harder to fight. One person infected with the virus carries hundreds of thousands of its variations, preventing the use of traditional vaccines that target a single version of a virus.

Starting from the so-called naive antibodies found in humans, scientists at The Scripps Research Institute in the United States are breeding a new class of smart antibodies, called broadly neutralising antibodies, that could protect against the whole spectrum of HIV mutations.
In this audio interview, lead researcher Dennis Burton says the method raises hopes for the development of a HIV vaccine.

Related topics